<VariationArchive VariationID="557052" VariationName="NM_000404.4(GLB1):c.846del (p.Thr283fs)" VariationType="Deletion" Accession="VCV000557052" Version="4" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-03-05" DateCreated="2018-08-05" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="543188" VariationID="557052">
      <GeneList>
        <Gene Symbol="GLB1" FullName="galactosidase beta 1" GeneID="2720" HGNC_ID="HGNC:4298" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3p22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="32961108" stop="33097146" display_start="32961108" display_stop="33097146" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33038099" stop="33138693" display_start="33038099" display_stop="33138693" Strand="-" />
          </Location>
          <OMIM>611458</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000404.4(GLB1):c.846del (p.Thr283fs)</Name>
      <CanonicalSPDI>NC_000003.12:33051950:GG:G</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="33051951" stop="33051951" display_start="33051951" display_stop="33051951" variantLength="1" positionVCF="33051950" referenceAlleleVCF="TG" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33093443" stop="33093443" display_start="33093443" display_stop="33093443" variantLength="1" positionVCF="33093442" referenceAlleleVCF="TG" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>T152fs</ProteinChange>
      <ProteinChange>T331fs</ProteinChange>
      <ProteinChange>T253fs</ProteinChange>
      <ProteinChange>T283fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.33093444del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.33093444del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.33051952del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.33051952del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009005.1" sequenceAccession="NG_009005" sequenceVersion="1" change="g.50252del">
            <Expression>NG_009005.1:g.50252del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.4" sequenceAccession="NM_000404" sequenceVersion="4" change="c.846del" MANESelect="true">
            <Expression>NM_000404.4:c.846del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000395.3" sequenceAccession="NP_000395" sequenceVersion="3" change="p.Thr283fs">
            <Expression>NP_000395.3:p.Thr283fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079811.3" sequenceAccession="NM_001079811" sequenceVersion="3" change="c.756del">
            <Expression>NM_001079811.3:c.756del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073279.2" sequenceAccession="NP_001073279" sequenceVersion="2" change="p.Thr253fs">
            <Expression>NP_001073279.2:p.Thr253fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001135602.3" sequenceAccession="NM_001135602" sequenceVersion="3" change="c.453del">
            <Expression>NM_001135602.3:c.453del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001129074.2" sequenceAccession="NP_001129074" sequenceVersion="2" change="p.Thr152fs">
            <Expression>NP_001129074.2:p.Thr152fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001317040.2" sequenceAccession="NM_001317040" sequenceVersion="2" change="c.990del">
            <Expression>NM_001317040.2:c.990del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001303969.2" sequenceAccession="NP_001303969" sequenceVersion="2" change="p.Thr331fs">
            <Expression>NP_001303969.2:p.Thr331fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001393580.1" sequenceAccession="NM_001393580" sequenceVersion="1" change="c.846del">
            <Expression>NM_001393580.1:c.846del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001380509.1" sequenceAccession="NP_001380509" sequenceVersion="1" change="p.Thr283fs">
            <Expression>NP_001380509.1:p.Thr283fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1553610382" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000404.4(GLB1):c.846del (p.Thr283fs) AND multiple conditions" Accession="RCV000673140" Version="1">
        <ClassifiedConditionList TraitSetID="10410">
          <ClassifiedCondition DB="MedGen" ID="C0268272">GM1 gangliosidosis type 2</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268273">GM1 gangliosidosis type 3</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268271">Infantile GM1 gangliosidosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0086652">Mucopolysaccharidosis, MPS-IV-B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-03-07" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.846del (p.Thr283fs) AND GM1 gangliosidosis type 2" Accession="RCV000987140" Version="1">
        <ClassifiedConditionList TraitSetID="245">
          <ClassifiedCondition DB="MedGen" ID="C0268272">GM1 gangliosidosis type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-05-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.846del (p.Thr283fs) AND GM1 gangliosidosis" Accession="RCV001175077" Version="1">
        <ClassifiedConditionList TraitSetID="11702">
          <ClassifiedCondition DB="MedGen" ID="C0085131">GM1 gangliosidosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-04-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.846del (p.Thr283fs) AND multiple conditions" Accession="RCV003768002" Version="1">
        <ClassifiedConditionList TraitSetID="10013">
          <ClassifiedCondition DB="MedGen" ID="C0085131">GM1 gangliosidosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0086652">Mucopolysaccharidosis, MPS-IV-B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-05-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-05-13" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2018-08-05" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17309651</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18524657</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21214877</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="10410" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1390" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis type 2</ElementValue>
                <XRef ID="MONDO:0009261" DB="MONDO" />
                <XRef ID="79256" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, juvenile type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Juvenile GM&gt;1&lt; gangliosidosis</ElementValue>
                <XRef ID="18756002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-GANGLIOSIDOSIS, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0022" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0003" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GLB1-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10126" />
                <XRef ID="10126" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79256" DB="Orphanet" />
              <XRef ID="C0268272" DB="MedGen" />
              <XRef ID="MONDO:0009261" DB="MONDO" />
              <XRef Type="MIM" ID="230600" DB="OMIM" />
              <Comment DataSource="NCBI curation" Type="public">REVIEWED: Set the orphanet value to preferred to avoid the annotation for the subscript</Comment>
            </Trait>
            <Trait ID="1939" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis type 3</ElementValue>
                <XRef ID="MONDO:0009262" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta-galactosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adult GM1 gangliosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Type 3 (adult) GM1 gangliosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-GANGLIOSIDOSIS, TYPE III</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0013" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0014" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2431" />
                <XRef ID="2431" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="79257" DB="Orphanet" />
              <XRef ID="C0268273" DB="MedGen" />
              <XRef ID="MONDO:0009262" DB="MONDO" />
              <XRef Type="MIM" ID="230650" DB="OMIM" />
            </Trait>
            <Trait ID="2965" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IVB (Morquio)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IV B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 4B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 4B</ElementValue>
                <XRef ID="MONDO:0009660" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
                <XRef ID="Morquio+syndrome+B/4877" DB="Genetic Alliance" />
                <XRef ID="238044004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS IVB</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis Type IVB</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS4B</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3786" />
                <XRef ID="3786" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="309310" DB="Orphanet" />
              <XRef ID="582" DB="Orphanet" />
              <XRef ID="C0086652" DB="MedGen" />
              <XRef ID="MONDO:0009660" DB="MONDO" />
              <XRef Type="MIM" ID="253010" DB="OMIM" />
            </Trait>
            <Trait ID="5204" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1 gangliosidosis type 1</ElementValue>
                <XRef ID="MONDO:0009260" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Infantile GM1 gangliosidosis</ElementValue>
                <XRef ID="238026007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-gangliosidosis, type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, infantile form</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB1 deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6479" />
                <XRef ID="6479" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79255" DB="Orphanet" />
              <XRef ID="C0268271" DB="MedGen" />
              <XRef ID="MONDO:0009260" DB="MONDO" />
              <XRef Type="MIM" ID="230500" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="245" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1390" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis type 2</ElementValue>
                <XRef ID="MONDO:0009261" DB="MONDO" />
                <XRef ID="79256" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, juvenile type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Juvenile GM&gt;1&lt; gangliosidosis</ElementValue>
                <XRef ID="18756002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-GANGLIOSIDOSIS, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0022" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0003" DB="OMIM" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GLB1-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10126" />
                <XRef ID="10126" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79256" DB="Orphanet" />
              <XRef ID="C0268272" DB="MedGen" />
              <XRef ID="MONDO:0009261" DB="MONDO" />
              <XRef Type="MIM" ID="230600" DB="OMIM" />
              <Comment DataSource="NCBI curation" Type="public">REVIEWED: Set the orphanet value to preferred to avoid the annotation for the subscript</Comment>
            </Trait>
          </TraitSet>
          <TraitSet ID="10013" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7352" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Beta galactosidase 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
                <XRef ID="MONDO:0018149" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10891" />
                <XRef ID="10891" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="C0085131" DB="MedGen" />
              <XRef ID="MONDO:0018149" DB="MONDO" />
            </Trait>
            <Trait ID="2965" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IVB (Morquio)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IV B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 4B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 4B</ElementValue>
                <XRef ID="MONDO:0009660" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
                <XRef ID="Morquio+syndrome+B/4877" DB="Genetic Alliance" />
                <XRef ID="238044004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS IVB</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis Type IVB</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS4B</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3786" />
                <XRef ID="3786" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="309310" DB="Orphanet" />
              <XRef ID="582" DB="Orphanet" />
              <XRef ID="C0086652" DB="MedGen" />
              <XRef ID="MONDO:0009660" DB="MONDO" />
              <XRef Type="MIM" ID="253010" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="11702" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7352" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Beta galactosidase 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
                <XRef ID="MONDO:0018149" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10891" />
                <XRef ID="10891" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="C0085131" DB="MedGen" />
              <XRef ID="MONDO:0018149" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1548613" SubmissionDate="2018-07-10" DateLastUpdated="2018-08-05" DateCreated="2018-08-05">
        <ClinVarSubmissionID localKey="574487|OMIM:230500;230600;230650;253010" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000798310" DateUpdated="2018-08-05" DateCreated="2018-08-05" Type="SCV" Version="1" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-03-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21214877</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17309651</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal Recessive and X-Linked Classification Criteria (2018)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/sbjulxjt/counsyl_autosomal_recessive_and_x-linked_classification_criteria_2018_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="3" alternateAllele="T" referenceAllele="TG" start="33093442" stop="33093443" variantLength="2" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.2:c.846delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230500" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230600" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230650" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="253010" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4282047</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2242160" SubmissionDate="2019-10-22" DateLastUpdated="2020-01-09" DateCreated="2020-01-09">
        <ClinVarSubmissionID localKey="NC_000003.11:g.33093443delG|OMIM:230600" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001136361" DateUpdated="2020-01-09" DateCreated="2020-01-09" Type="SCV" Version="1" SubmitterName="Mendelics" OrgID="500035" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-05-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Mendelics Assertion Criteria 2017</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/chhjzatu/mendelics_assertion_criteria_2017.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.33093443delG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230600" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>MENDELICS_CLINVAR_020</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2645996" SubmissionDate="2020-05-13" DateLastUpdated="2020-06-18" DateCreated="2020-06-18">
        <ClinVarSubmissionID localKey="NM_000404.3:c.846delC|MedGen:C0085131" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001338637" DateUpdated="2020-06-18" DateCreated="2020-06-18" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-04-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17309651</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21214877</ID>
          </Citation>
          <Comment>Variant summary: GLB1 c.846delC (p.Thr283GlnfsX21) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 249510 control chromosomes (gnomAD). c.846delC has been reported in the literature in individuals affected with GM1 gangliosidosis (e.g. Coutinho_2012, Santamaria_2007). These data indicate that the variant is likely to be associated with disease. Two ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.3:c.846delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0085131" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7441258</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8524473" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2024-02-28">
        <ClinVarSubmissionID localKey="4374809|MedGen:C0086652;C0085131" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004569314" DateUpdated="2024-02-28" DateCreated="2024-02-28" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17309651</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21214877</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18524657</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 557052). This premature translational stop signal has been observed in individual(s) with GM1-gangliosidosis (PMID: 17309651, 21214877). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Thr283Glnfs*21) in the GLB1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLB1 are known to be pathogenic (PMID: 18524657).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.33093443del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0086652" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085131" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14224806</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1548613" TraitType="Disease" MappingType="XRef" MappingValue="253010" MappingRef="OMIM">
        <MedGen CUI="C0086652" Name="Mucopolysaccharidosis, MPS-IV-B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2645996" TraitType="Disease" MappingType="Name" MappingValue="GM1 gangliosidosis" MappingRef="Preferred">
        <MedGen CUI="C0085131" Name="GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1548613" TraitType="Disease" MappingType="XRef" MappingValue="230650" MappingRef="OMIM">
        <MedGen CUI="C0268273" Name="GM1 gangliosidosis type 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8524473" TraitType="Disease" MappingType="XRef" MappingValue="C0086652" MappingRef="MedGen">
        <MedGen CUI="C0086652" Name="Mucopolysaccharidosis, MPS-IV-B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1548613" TraitType="Disease" MappingType="XRef" MappingValue="230600" MappingRef="OMIM">
        <MedGen CUI="C0268272" Name="GM1 gangliosidosis type 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2242160" TraitType="Disease" MappingType="XRef" MappingValue="230600" MappingRef="OMIM">
        <MedGen CUI="C0268272" Name="GM1 gangliosidosis type 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8524473" TraitType="Disease" MappingType="XRef" MappingValue="C0085131" MappingRef="MedGen">
        <MedGen CUI="C0085131" Name="GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1548613" TraitType="Disease" MappingType="XRef" MappingValue="230500" MappingRef="OMIM">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

